Bayer
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer's products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed 118,900 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion.
Business & Industry
- Novartis acquires Arctos Medical, expanding optogenetics portfolio to bring gene therapies to patients with severe vision loss
- Pfizer and BioNTech announce positive topline results from pivotal trial of COVID-19 vaccine in children 5 to 11 years
- University of Oxford and Oracle Cloud System helping researchers identify COVID-19 variants faster
- Roche opens access to pathology imaging tools to improve patient care
- Pfizer and BioNTech submit a variation to EMA with the data in support of a booster dose of COMIRNATY®
Research & Development
- Therapy using dual immune system cells effectively controls neuroblastoma
- COVID-19 nasal vaccine candidate effective at preventing disease transmission
- How a plant virus could protect and save your lungs from metastatic cancer
- Scientific evidence to date on COVID-19 vaccine efficacy does not support boosters for general population
- NIH scientists build a cellular blueprint of multiple sclerosis lesions
- First-in-human clinical trial for a vaccine to treat opioid use disorders enrolls first patients
- No serious health effects linked to mRNA COVID-19 vaccines
Conferences & Events
- Novartis, Bayer and Boehringer Ingelheim to showcase their commitment to a reimagined pharma industry
- Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
Regulatory Affairs
- FDA authorizes software that can help identify prostate cancer
- FDA advances data, IT modernization efforts with new office of digital transformation
- ECDC and EMA highlight considerations for additional and booster doses of COVID-19 vaccines
- FDA approves first COVID-19 vaccine
- FDA approves new treatment for Pompe disease